Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Machine Learning-Based Prediction of Recurrence Risk in Allergic Bronchopulmonary Aspergillosis and Its Clinical Decision-Making Value: A Multicenter Study With External Validation

NCT07714863 is registered in ClinicalTrials.gov with Qianfoshan Hospital as lead sponsor.

NCT NCT07714863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07714863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Machine Learning-Based Prediction of Recurrence Risk in Allergic Bronchopulmonary Aspergillosis and Its Clinical Decision-Making Value: A Multicenter Study With External Validation
Lead sponsor
Qianfoshan Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2021
Completion date
December 31, 2028
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abpa, acute exacerbation, allergic bronchopulmonary aspergillosis, allergic bronchopulmonary aspergillosis (abpa), machine learning